| C |
|
C/EBP
|
| De Wolf C. J. F., Bertina R. M., Vos H. L. |
| |
|
Calcium- and integrin-binding (CIB) protein is required for platelet spreading on immobilized fibrinogen: functional association of CIB with GPIIb/IIIa
|
| Naik M. U., Naik U. P. |
| |
|
Calcium ion-independent structure of the factor IX w-loop peptide, FIX(G4–Q11) and its interaction with phosphatidylserine
|
| Grant M. A., Baikeev R., Gilbert G. E., Rigby A. C. |
| |
|
Calcium ionophore A23187 and convulxin increase Xa generation in a cell-based model of hemostasis
|
| Kempton C. L., Roberts H. R., Monroe D. M. |
| |
|
Calpain inhibitor calpeptin enhances the activity of the 20S proteasome in intact and calcium ionophore-stimulated platelets
|
| Ostrowska J., Dabrowska M., Radziwon P., Ostrowska H. |
| |
|
cAMP inhibits convulxin-induced calcium mobilization; differences with collagen
|
| Riondino S., Treppiccione A., Lambiasi M. G., Pulcinelli F. M. |
| |
|
Can full-length wild-type von Willebrand factor (VWF) or the VWF propeptide rescue secretion of the R273W VWF variant associated with quantitative deficiency?
|
| Marsden L., Peake I. R., Daly M. E., Croft S. A. |
| |
|
Carbon disulfide and low-level ionizing irradiation: causes of hypercoagulable state, impair cell–cell communication and accelerated atherosclerosis
|
| Kruchinsky N. G., Teplyakov A. I. |
| |
|
Carboxypeptidase U (TAFIa) prevents fibrinolysis from proceeding into the propagation phase through a threshold-dependent mechanism
|
| Leurs J., Nerme V., Sim Y., Hendriks D. |
| |
|
Carboxy-terminal mutations render heparin cofactor II more susceptible to secretory impairment than equivalent mutations in antithrombin
|
| Bhakta V., Begbie M. E., Gupta A., Sandhu V., Sheffield W. P. |
| |
|
Case study on HIT
|
| Lewis B. |
| |
|
Cases of development of an idiopathic thrombocytopenic purpura at children associated with introduction of a tuberculin
|
| Petrov V. Y., Plahuta T. G., Yakunina L. N., Soskov G. I., Vdovin V. V. |
| |
|
Catheter-related venous thrombosis in children diagnosed by magnetic resonance venography
|
| Chalmers E. A., McIntosh N., Gibson B. E. S., Watt A. J. |
| |
|
CD39 ecto-nucleotidase activity (metabolizing ATP to ADP to AMP) constitutes a homeostatic mechanism for control of platelet reactivity, depending on the ratio of ADPase to ATPase activity. Results from patients with coronary artery disease
|
| Marcus A. J., El-Omar M. M., Islam N., Broekman M. J., Drosopoulos J. H. F., Roa D. C., Lorin J., Sedlis S. P., Sesti C., Levi R., Pinsky D. J. |
| |
|
CD47 stimulated sickle erythrocytes adhere to activated monocytes via a novel contribution of the a 4b 1 integrin from each cell type
|
| Brittain J. E., Orringer E. P., Parise L. V. |
| |
|
CD84 signaling is a novel platelet stimulatory mechanism that occurs during platelet aggregation
|
| Nanda N., Bao M., Clauser K., Phillips D. R. |
| |
|
cDNA sequence of the nonenzymatic subunit of pseutarin C, a prothrombin activator from the eastern brown snake (Pseudonaja textilis): its structural similarity to blood coagulation factor V
|
| Rao V. S., Swarup S., Kini R. M. |
| |
|
Cell lines expressing recombinant platelet membrane glycoprotein isoforms as tools for the characterization of antibodies against low frequency alloantigens in neonatal alloimmune thrombocytopenia
|
| Kroll H., Yates J., Santoso S. |
| |
|
Cell surface annexin A2 (ANX2) mediates the up-regulation of monocyte tissue factor activity by b2-glycoprotein I (b2GPI) and anti-b2GPI autoantibodies
|
| Zhou H., Roubey R. A. S. |
| |
|
Cellular microparticles, what are they bad or good for?
|
| Freyssinet J. M. |
| |
|
Cellulitis and deep vein thrombosis: a controversial association
|
| Bounameaux H., Bersier D. E. |
| |
|
Central venous catheter (CVC) related thrombosis in boys with hemophilia
|
| Price V., Stain A. M., Chait P., Connolly B., Temple M., Daneman A., Carcao M., Blanchette M. |
| |
|
Central venous catheter-related thrombosis presenting as SVC syndrome in a hemophiliac with inhibitors
|
| Carcao M., Connolly B. L., Chait P., Stain A. M., Acebes M., Massicotte P., Blanchette V. S. |
| |
|
Central venous line-related thrombotic events in children: association with duration of line placement, type, size, and location
|
| Male C., Mitchell L., Julian J., Massicotte P., Andrew M., Gent M., PROTEKT INVESTIGATORS¶ |
| |
|
Cerebral sinovenous thrombosis (SVT) in children: a prospective 10-year registry in Argentina
|
| Bonduel M., Sciuccati G., Hepner M., Pieroni G., Feliu Torres A., Frontroth J., Serviddio M. R. |
| |
|
Cerebral venous sinus thrombosis. The spectrum of risk associated with this unique thrombotic disorder
|
| Gosk-Bierska I., Wysokinski W. E., Karnicki K., Mcbane R. D. |
| |
|
Cerivastatin neither inhibits thrombin generation nor decreases markers of inflamation in patients with APS
|
| Musial J., Swadzba J., Motyl A., Rys A., Iwaniec T., Sydor W., Szczeklik A. |
| |
|
cGMP regulates thrombopoietin-induced CD34+ human stem cell proliferation and differentiation into megakaryocytes
|
| Kobsar A., Heeg S., Krohne K., Opitz A., Rath J., Wilhelm M., Lohmann S. M., Böck M., Eigenthaler M. |
| |
|
Changed inactivation pathway of factor Va by activated protein C in the presence of heparin
|
| Nicolaes G. A. F., Sørensen K. W., Friedrich U., Rosing J., Tans G., Autin L., Villoutreix B. O., Dahlbäck B. |
| |
|
Changes at thromboprophylaxis in a Peruvian hospital from 1996 to 2000
|
| Cotrina R., Cordova F., Rivera S. |
| |
|
Changes in ADAMTS13 (vWF cleaving protease) activity after induced acute release of von Willebrand factor
|
| Knöbl P., Varadi K., Reiter R., Jilma B., Schwarz H. P., Turecek P. L. |
| |
|
Changes in hemostatic system in oncogynecologic patients
|
| Bizadze V. O., Tabakman U. U., Chabrov A. M., Choporev L. |
| |
|
Changes in homocysteine and lipid peroxidation by n-3 polyunsaturated fatty acids (PUFAs) administered after an acute myocardial infarction
|
| Grundt H., Nilsen D. W. T., Mansoor M. A. |
| |
|
Changes in the platelet count (PC) after cardiopulmonary bypass (CPB) can efficiently predict the development of pathogenic heparin- dependent antibodies (Abs)
|
| Gruel Y., Pouplard C., May M. A., Regina S., Maakaroun A., Fusciardi J. |
| |
|
Changes in thromboelastography in low-risk women in the puerperium
|
| Gornall A., Maybury H., Descals E., Kurinczuk J., Konje J., Oppenheimer C., Pavord S. |
| |
|
Changes in von Willebrand factor concentration and blood loss during cardiac surgery
|
| Raszeja-Specht A., Juscinski J., Skibowska A., Czajkowska E., Roszak K., Szutowicz A. |
| |
|
Changes of hemostatic parameters in patients with non-ST elevation acute coronary syndrome treated with atorvastatin or pravastatin (randomized comparative study)
|
| Pokrovskaya E., Averkov O. V., Vaulin N. A., Slavina N. N., Gratsiansky N. A. |
| |
|
Characterization and preliminary crystallographic studies of EMS16, an antagonist of collagen receptor (GPIa/IIa) from the venom of Echis multisquamatus
|
| Okuda D., Horii K., Mizuno H., Morita T. |
| |
|
Characterization of 5'-upstream region of human phospholipase C-beta2 gene in megakaryocytic cell line
|
| Mao G., Kunapuli S. P., Rao A. K. |
| |
|
Characterization of a lupus anticoagulant positive monoclonal antibody against human prothrombin
|
| Arnout J., Boon D., Vandervoort P., Vanrusselt M., Vermylen J. |
| |
|
Characterization of a mixed disulfide intermediate between the propeptide and the mature subunit of von Willebrand Factor during multimer formation
|
| Purvis A., Tuley E. A., Sadler J. E. |
| |
|
Characterization of a monoclonal antibody to factor VIII: epitope mapping and mechanism of inhibition
|
| Ulmasov B., Zhong D., Fay P., Bajaj S. P. |
| |
|
Characterization of a new therapeutic recombinant human anti-thrombin concentrate
|
| Cooper P. C., Cooper S. M., Kitchen S., Makris M. |
| |
|
Characterization of a thrombomodulin binding site on protein C and its distinction from an activated protein C binding site for factor Va
|
| Gale A. J., Griffin J. H. |
| |
|
Characterization of an immunologic polymorphism in the heavy chain of human factor V, due to a dimorphism of residue 79
|
| Van Der Neut Kolfschoten M., Dirven R. J., Van Wijk R., Vos H. L., Bertina R. M. |
| |
|
Characterization of anti-factor VIII antibodies using Time-Resolved Fluoroimmunoassay
|
| Sumiya M., Davies I., Shima M., Yoshioka A., Savidge G., Alhaq A. |
| |
|
Characterization of high level expression sequence determinants within porcine factor VIII
|
| Doering C. B., Healey J. F., Parker E. T., Barrow R. T., Lollar P. |
| |
|
Characterization of monoclonal antibodies that inhibit either the activation of proCPU (TAFI) or the activity of CPU (TAFIa)
|
| Gils A., Ceresa E., Peeters M., Brouwers E., Declerck P. J. |
| |
|
Characterization of mutations in a cohort of type 2 von Willebrand disease patients
|
| Nesbitt I. M., Makris M., Hamptom K. K., Peake I. R., Goodeve A. C. |
| |
|
Characterization of mutations of the factor VIII gene in Korean hemophilia A patients
|
| Han J. Y., Kim K. H., Choi O. H., Kim I. J., Kim C. M. |
| |
|
Characterization of novel platelet and procoagulant activities from Bothrops cotiara snake venom
|
| Senis Y. A., Fuller G. L. J., Brittan H., Warrell D., Watson S. P., Kamiguti A. S., Theakston R. D. G., Laing G. |
| |
|
Characterization of protein Kinase B/Akt activation and its role in thrombin and thrombin receptor-activating peptide-induced platelet activation
|
| Kim S., Kunapali P. |
| |
|
Characterization of the anti-apoptotic effect of activated protein C
|
| Mosnier L. O., Gale A. J., Griffin J. H. |
| |
|
Characterization of the interaction of alpha-thrombin with melagatran analogs with different P3 substituents: a kinetic and thermodynamic study
|
| Deinum J., Gyzander E., Gustavsson L. |
| |
|
Characterization of the specific interaction between plasminogen and b2-glycoprotein I
|
| Lopez Lira F., Anglés-Cano E. |
| |
|
Characterization of the urinary metabolites of dipetarudin
|
| Lopez M., Mende K., Nowak G. |
| |
|
Characterization of the von Willebrand factor present in circulating PMN
|
| Maugeri N., Kempfer A. C., Savino J., Pozner R. G., Negrotto S., Amaral M. M., Schattner M., Lazzari M. A. |
| |
|
Chemotherapy-induced activation of hemostasis: the role of d-dimer
|
| Siragusa S., Lo Coco L., Minardi V., Fulfaro F., Arcara C., Anastasio R., Malato A., Schiralli F., Riina M. F., Dolce A., Gebbia N., Mariani G. |
| |
|
Cholesterol and caveolin modulate the cell surface distribution and activity of TFPI
|
| Lupu C., Westmuckett A. D., Lupu F. |
| |
|
Cholesterol-microdomains in platelet adhesion and aggregation
|
| Van Lier M., Ohno Iwashita Y., Akkerman J. W. N., Heijnen H. F. G. |
| |
|
Chronic paclitaxel exposure increases human endothelial expression of plasminogen activator inhibitor-1, tissue-type plasminogen activator and tissue inhibitor of metalloproteinase-1
|
| Muldowney J., Painter C. A., Levy S. E., Piana R. N., Vaughan D. E. |
| |
|
Circulating activated protein C in Behcet's disease and risk of thrombosis
|
| España F., Vayá A., Villa P., Todolí J., Calvo J., Ricart J. M., Medina P., Estellés A., Navarro S., Micó M. L., Aznar J. |
| |
|
Circulating microparticles: a marker of procoagulant state in normal pregnancy and pregnancy complicated by preeclampsia or intrauterine growth retardation
|
| Dignat-George F., Bretelle F., Sabatier F., Desprez D., Camoin-Jau L., Grunebaum L., D'Ercole C., Combes V., Dignat-George F. |
| |
|
Circulating prostaglandin E2 is associated with high risk of coronary heart disease in asymptomatic subjects: a novel inflammatory marker of subclinical atherosclerosis
|
| Páramo J. A., Beloqui O., Orbe J., Monasterio A., Coma I., Colina I., Díez J. |
| |
|
Circulating vascular cell adhesion molecule-1 in patients with operable breast cancer
|
| Hyun Kyung K., Kyoung Rhan L., Eun Sook L., Kyung Soon S. |
| |
|
Classification of VWD on the move
|
| Schneppenheim R. |
| |
|
Clear familial co-segregation of the type 1 von Willebrand disease phenotype and VWF haplotypes in the Canadian type 1 VWD study
|
| James P., Cameron C. L., Notley C. R. P., O'Brien L. A., Hegadorn C. A., Hough C., Rivard G. E., AHCDC‡ , Lillicrap D. P. |
| |
|
Cleavage of factor VIII heavy chain by thrombin increases the affinity for low-density lipoprotein receptor-related protein (LRP)
|
| Bovenschen N., Van Stempvoort G., Voorberg J., Mertens K., Meijer A. B. |
| |
|
Clinical and laboratoristic performance evaluation of three point-of-care devices for INR determination (Coagucheck, ProTime, Harmony)
|
| Accardo P., Ghirarduzzi A., Silingardi M., Franzoni C., Iorio A. |
| |
|
Clinical and laboratory findings in a new case of congenital amegakaryocytic thrombocytopenia (CAMT)
|
| Trichet C., Guiheneuf C., Ballmaier M., Germeshausen M., Nurden P., Bader-Meunier B., Tchernia G., Dreyfus M. |
| |
|
Clinical data of subjects with Factor V Leiden or G20210A prothrombin mutation: a single institution experience
|
| Iannaccaro P., Santaro R., Muleo G. |
| |
|
Clinical evaluation of an advanced category recombinant FVIII, anti-hemophilic factor (recombinant) plasma/albumin-free method (rAHF-PFM) in pediatric previously treated patients (PTPs)
|
| Hoots W. K., Blanchette V., Shapiro A., Navale L., Spotts G., Rogy S., Ewenstein B. |
| |
|
Clinical evaluation of an advanced category recombinant FVIII, anti-hemophilic factor (recombinant) plasma/albumin-free method (rAHF-PFM) in surgical settings
|
| Astermark J., Negrier C., Schroth P., Yi S., Tonetta S., Ewenstein B. |
| |
|
Clinical experience with optional cava filters
|
| Barral F., Tardy B., Guillot K., Laporte S., Decousus H., Mismetti P. |
| |
|
Clinical manifestation and therapy in children with hereditary angioedema (HAE) – a prospective follow up
|
| Rusicke E., Martinez-Saguer I., Aygören-Pürsün E., Heller C., Becker S., Funk M., Klarmann D., Müller W., Stoll H., Klingebiel T., Kreuz W. |
| |
|
Clinical manifestation of severe hemophilia B ameliorated by Prothrombin 20210A
|
| Jaloma-Cruz A., Beltrán-Miranda C. P., Mantilla-Capacho J. M., Martínez V., Benítez H., Benítez H., Vinciguerra C., Negrier C., Laffan M. |
| |
|
Clinical manifestations of the antiphospholipid syndrome in patients with highly elevated anticardiolipin antibodies
|
| Miesbach W., Asmelash G., Vigh T., Pütz B., Scharrer I. |
| |
|
Clinical outcomes and medical resource utilization in patients with and without malignancy treated with warfarin
|
| Wittkowsky A. K., Veenstra D., Blough D. |
| |
|
Clinical outcomes with the use of unfractionated heparin or low-molecular-weight heparin as perioperative bridging therapy in patients on long-term oral anti-coagulants: Rationale, objectives, and design of a large, long-term study (REGIMEN)
|
| Spyropoulos A. C., Turpie A. G. G., Dunn A., Spandorfer J., for the Regimen Investigators |
| |
|
Clinical presentation of type 1 von Willebrand disease (VWD) in obligatory carriers: final results from a collaborative, international, multicenter study
|
| Castaman G., Tosetto A., Cappelletti A., Rodeghiero F., Battle J., Baudo F., Blomback M., Castillo R., De Bosch N., Federici A. B., Eikenboom J. C. J., Lethagen S., Lusher J., Linari S., Monteagudo J., Nishino M., Srivastava A. |
| |
|
Clinical profile of rare coagulation disorders in an Asian population
|
| Tien S. L., Fong S. Z., Chiang T., Ng G. M. |
| |
|
Clinical quality assessment program for the oral anti-coagulant clinic: preliminary report of a multicentric Italian exercise
|
| Iorio A., Testa S., Parisoli A., Alatri A., Franzoni M., Trottini S., Cinotti R., Rinaldi G., Ghirarduzzi A. |
| |
|
Clinical significance of endothelial hemostatic markers in patients with ischemic heart disease
|
| Ihara A., Kawamoto T., Matsumoto K. |
| |
|
Clinical thrombolytic trial of a new type of tissue-plasminogen activator in patients with acute stroke
|
| Feng Y., Ye X., Fu M. S. |
| |
|
Clinical trial to evaluate the safety and efficacy of an Internet-based system for supervised self-management of oral anti-coagulant therapy
|
| O'Shea S., Arcasoy M. O., Thames E. H., Ortel T. L. O. |
| |
|
Clinical usefulness of D-dimer according to clinical probability in patients with suspected pulmonary embolism
|
| Righini M., Aujesky D., Roy P. M., Cornuz J., De Moerloose P., Bounameaux H., Perrier A. |
| |
|
Clinical usefulness of D-dimer in cancer patients with suspected pulmonary embolism
|
| Perrier A., De Lucia S., Aujesky D., Roy P. M., Cornuz J., De Moerloose P., Bounameaux H. |
| |
|
Clinicopathological findings and response to treatment in childhood and adult immune thrombocytopenic purpura
|
| Murari M., Sharma S., Pandey R. |
| |
|
Cloning and expression of full-length recombinant porcine von Willebrand factor
|
| Fahs S. A., Nichols T. C., Bellinger D. A., Montgomery R. R. |
| |
|
Clopidogrel and ticlopidine induced experimental hemorrhagia and possibility it's correction with help vasopressin analogue DGAVP
|
| Golubeva M., Grigorjeva M. |
| |
|
Clopidogrel in non-ST-elevation acute coronary syndrome: effect on parameters of fibrinolysis and blood coagulation
|
| Averkov O., Slavina N. N., Dobrovolsky A. B., Gratsiansky N. A. |
| |
|
Clopidogrel inhibits collagen-induced platelet recruitment in whole blood
|
| Pérez-Requejo J. |
| |
|
Clopidogrel plus aspirin in the prevention of thromboembolism in cardioverted atrial fibrillation: results of the clopidogrel aspirin atrial fibrillation (CLAAF): a pilot study
|
| De Caterina R., Lorenzoni R. |
| |
|
Clopidogrel suppresses rebound coagulation after discontinuation of enoxaparin treatment in patients with acute coronary syndromes
|
| Di Nisio M., Bijsterveld N. R., Meijers J. C. M., Levi M., Buller H. R., Peters R. J. G. |
| |
|
Clopidogrel treatment provides limited protection against exercise-induced platelet-leukocyte conjugation
|
| Hu H., Perneby C., Li N., Daleskog M., Johansson M. C., Wallén N. H., Hjemdahl P. |
| |
|
Clopidogrel treatment reduces platelet activity in vivo, but does not counteract exercise-induced platelet activation
|
| Perneby C., Hu H., Li N., Daleskog M., Johansson M.-C., Wallén N. H., Hjemdahl P. |
| |
|
Clot from platelet rich plasma promotes wound healing
|
| Luboshitz J., Lalezari S., Dardik R. |
| |
|
Clot penetration and fibrin binding of amediplase
|
| Rijken D. C., Barrett-Bergshoeff M. M., Jie A. F. H., Sakharov D. V. |
| |
|
Coagulant phenotype determines the outcome of septic peritonitis
|
| Schoenmakers S. H. H. F., Brüggemann L. W., Reitsma P. H., Spek C. A. |
| |
|
Coagulation abnormalities in dengue virus infections: more common than currently perceived?
|
| Mairuhu A. T. A., Setiati T. E., Mac gillavry M. R., Meijers J. C. M., Setiawan H., Keller T. T., Soemantri A. G., Cate H., Van Gorp E. C. M., Brandjes D. P. M. |
| |
|
Coagulation activation in factors VIII and IX deficiency: a mathematical model
|
| Khanin M., Kuzmin V. M. |
| |
|
Coagulation activation markers in atrial fibrillation: dose-dependent correlation with warfarin therapy
|
| Tait R., Lowe G. D. O., Rumley A., Mcmahon A. D., O'Neill K. F., Wallace I. W., Jackson J., Murdoch D. L. |
| |
|
Coagulation and complement inhibitors levels predict outcome in patients with severe sepsis
|
| Siragusa S., Lo Coco L., Schiralli F., Riina F., Minardi V., Malato A., Raineri S. M., Giarratano A., D'Angelo U., Donzelli M., Federico A. |
| |
|
Coagulation and endothelium activation in patients with scrub typhus
|
| Toulon P., Dumont B., Burnouf T., Watt G. H. |
| |
|
Coagulation and fibrinolysis during the menstrual cycle and the effects of increased body mass index
|
| Koh S., Prasad R. N. V., Fong Y. F., Chua S. E., Yuen W. K., Ng B. L. |
| |
|
Coagulation disorders in b-thalassemic patients in Southern Iran
|
| Karimi M., Rahiminejad M. S., Karamimagham T. |
| |
|
Coagulation factor content of solvent/detergent plasma compared to fresh frozen plasma
|
| O'Donnell J., Doyle S., Murphy K., Fleming C., O'Brien P. |
| |
|
Coagulation factor immunogenicity: where are we going?
|
| Saint-Remy J. M. |
| |
|
Coagulation factor profiles respond strongly during human endotoxemia
|
| Reitsma P. H., Branger J., Van Den Blink B., Weijer S., Van Der Poll T., Meijers J. C. M. |
| |
|
Coagulation factor V in normal bronchial epithelial and lung cancer cells
|
| Salge U., Wimmel A., Heiden M., Seitz R. |
| |
|
Coagulation factor V Leiden not increased in pregnancies complicated by abruptio placentae
|
| Procházka M., Happach C., Marsál K., Dahlback B., Lindqvist P. G. |
| |
|
Coagulation factor XII activity, but not an associated common genetic polymorphism, is linked to recurrent miscarriage
|
| Sugiura-Ogasawara M., Linuma Y., Ozaki Y., Suzumori K. |
| |
|
Coagulation inhibitor monitoring rationale in critical patients with severe sepsis
|
| Isvarlal P., Marinho A., Pereira I., Polo S., Lau C., Moura P., Pinho N., Matos E., Brandão M., Campos M., Justiça B. |
| |
|
Coagulation proteases factor Xa and factor VIIa do not mobilize intracellular calcium stores in human dermal fibroblasts
|
| Pech C. M., Bachli E. B., Tuddenham E. G. D., McVey J. H. |
| |
|
Coagulation system and inflammation significantly contribute to thrombus formation in ruptured plaques than erosive plaques of acute myocardial infarction
|
| Sato Y., Marutsuka K., Hatakeyama K., Sumiyoshi A., Asada Y. |
| |
|
Coagulation, fibrinolysis and platelet activity in aspirin-naive and prior aspirin users unstable angina patients, treated with unfractionated heparin
|
| Dotsenko O., Dotsenko O. R., Netiazhenko V. Z., Netiazhenko V. Z., Netiazhenko V. Z. |
| |
|
Coexistence of multiple hemostatic genetic risk factors does not increase risk of coronary heart disease: The ARIC Study results
|
| Matijevic-Aleksic N., Ahn C., Afshar-Kharghan V., Sweetman R., Lopez J. A., Nugent D. J., Boerwinkle E., Wu K. K. |
| |
|
Collagen induces tyrosine phosphorylation of signaling proteins in Fc receptor g-chain-deficient platelets
|
| Jarvis G. E., Watson S. P. |
| |
|
Collagen-platelet interactions in vivo
|
| Nieswandt B. |
| |
|
Co-localization of c-AMP-dependent PKA with eNOS in endothelial cell junctions: a clue for regulated NO production
|
| Heijnen H. F. G., Waaijenborg S., Crapo J., Bowler R., Akkerman J. W. N., Slot J. W. |
| |
|
Colocalization of recombinant human factor VIIa with its substrates on highly procoagulant COAT-platelets
|
| Kjalke M., Rojkjaer R. |
| |
|
Combination of increased vascular thrombogenesity and blood flow alteration promote obstructive thrombus formation in rabbit femoral artery
|
| Yamashita A., Marutsuka K., Furukoji E., Tamura S., Asada Y. |
| |
|
Combination therapy with low-molecular weight heparin and glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE)
|
| Agnelli G., Cannon C. P., Van De Werf F., Avezum A., Montalescot G., Lankes W., Kennelly B. M., Mazurek T., Kasper R. S., Brieger D. |
| |
|
Combination therapy with low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE)
|
| Agnelli G., Cannon C. P., Van De Werf F., Avezum A., Montalescot G., Lankes W., Kennelly B. M., Mazurek T., Kasper R. S., Brieger D. |
| |
|
Combined analysis of 2 studies on the clinical outcome over 6 months in patients with symptomatic acute deep vein thrombosis initially treated with one low-molecular-weight heparin
|
| Harenberg J., Bueller H., Huismann M., Riess H., Brom J., Weidinger G. |
| |
|
Combined anti-thrombotic protection of vascular wall with bienzyme superoxide dismutase–chondroitin sulphate–catalase conjugate in vivo
|
| Maksimenko A., Golubykh V., Tischenko E. |
| |
|
Combined carrier status of prothrombin 20210 A and factor XIII-A L34 alleles as a strong risk factor for myocardial infarction: evidence of a gene–gene interaction
|
| Butt C., Zheng H., Randell E., Robb D., Parfery P., Xie Y. G. |
| |
|
Combined effects of eptifibatide and melagatran on thrombin generation and platelet aggregation inhibition
|
| Koestenberger M. |
| |
|
Combined mechanical and pharmacologic thrombolysis for ilio-femoral deep venous thrombosis. Single center short-term outcomes
|
| Bjarnason H., Misra S., Mckusick M. A., Andrews J. C., Mcphail I. R., Sabater E. A., Johnson C. M., Stanson A. W. |
| |
|
Combined modality inhibitor eradication in a patient with mild hemophilia A and comparison of methods of inhibitor monitoring
|
| Coppell J. A., Millar C. M., Brooks S. V., Riddell A. F., Pollars D. A., Subel B., Yee T. T., Brown S. A. |
| |
|
Commercially available protein infusion solutions can be modified by nonenzymatic glycation which causes NFkappaB-dependent expression of procoagulant and inflammatory gene products
|
| Humpert P., Hong M., Schleicher E., Nawroth P. P., Bierhaus A. |
| |
|
Common genetic abnormalities in blood coagulation (Factor V Leiden, prothrombin G20210A) increase the incidence of central vein catheter related thrombosis
|
| Van Rooden C. J., Rosendaal F. R., Van Der Meer F. J. M., Van Oostayen J. A., Meinders A. E., Huisman M. V. |
| |
|
Comparability study of two purification processes of a plasma-derived anti-thrombin
|
| Chenou C., Bonnefond M., Nony E., Bihoreau N., Chtourou S. |
| |
|
Comparative analysis of methods for detection of Activated Protein C resistance: an analysis of 755 consecutive patients
|
| Matos M. F., Franco R. F., Silva C. R. S. S., Villela M. S. H., Figueiredo M. S. |
| |
|
Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis – a meta-analysis
|
| Gruppo R. A., Brown D., Wilkes M. M., Navickis R. J. |
| |
|
Comparative evaluation of a new automated latex agglutination d-dimer assay for exclusion of deep vein thrombosis
|
| Engelhardt W., Palareti G., Legnani C., Gringel E. |
| |
|
Comparative evaluation of four rapid quantitative D-dimer assays
|
| Coen D., Zovko V., Zivkovic M., Zadro R. |
| |
|
Comparative expression of recombinant wildtype and mutant von Willebrand factor cleaving protease ADAMTS13
|
| Schneppenheim R., Angerhaus D., Mainusch K., Obser T., Oyen F., Budde U. |
| |
|
Comparative molecular modeling of the nonenzymatic subunit of pseutarin C, a prothrombin activator from the venom of eastern brown snake
|
| Rao V. S., Joseph J. S., Kini R. M. |
| |
|
Comparative response of plasma VWF in normal and von Willebrand disease dogs to up-regulation of VWF mRNA by Interleukin-11 vs. Weibel–Palade body release by Desmopressin (DDAVP)
|
| Olsen E. H. N., Mccain A. S., Merricks E. P., Fisher T. A., Dillon I. M., Raymer R. A., Fahs S. A., Montgomery R. R., Keith J. C., Schaub R. G., Nichols T. C. |
| |
|
Comparative study of conformation sensitive gel electrophoresis and DNA sequencing for polymorphisms and mutation detection in von Willebrand disease type 2 N
|
| Carballo G. A., Kempfer A. C., Woods A. I., Farías C. E., Lazzari M. A. |
| |
|
Comparative study of the effect of recombinant factor VIIa on clot growth and thrombin generation in normal and hemophilia A plasma in vitro
|
| Ovanesov M. V., Sinauridze E. I., Panteleev M. A., Plyushch O. P., Kopylov K. G., Lopatina E. G., Ataullakhanov F. I. |
| |
|
Comparison and diagnostic value of two different D-dimer methods in the clinical laboratory
|
| Kalokyri E., Tzagaroulaki S., Afentoulidou K., Kozyri A., Theodorou E., Loulakis Z., Kopanakis C., Pombodakis C., Sfyraki N., Koumbanis B., Tsakiri M., Glambedaki M. |
| |
|
Comparison of 2 d-dimer assays (MDA®d-dimer and Tina-quant®d-dimer) in patients with suspected recurrent deep venous thrombosis – an interim analysis
|
| El Kheir D., Koopman M.M.W., Bakhtiari K., Buller H.R. |
| |
|
Comparison of a computer-based dosing program ‘Trombo’ with a manual dosing to monitor anti-coagulant therapy
|
| Mavri A., Primoziè R. |
| |
|
Comparison of Clauss fibrinogen and fibrinogen measurement derived from aPTT and PT in diabetes mellitus and correlations with markers of glycemic equilibration
|
| Sobas F., Hanss M., Dechavanne M., Riou J. P., Drai J., Negrier C. |
| |
|
Comparison of cytokine-induced transcriptional factor response in HCAEC and HUVEC cell types
|
| De Staercke C., Hooper W. C. |
| |
|
Comparison of cytotrophoblast gene expressed in normal and pre-eclamptic placenta
|
| Beauchamp N. J., Makris M., Fairlie F. M., Daly M. E. |
| |
|
Comparison of fibrinogen and S2238 as substrates for the study of multiple, active thrombin forms in the process of plasma clotting
|
| Pajdak W., Radwan J. |
| |
|
Comparison of FVIII levels as venous thrombosis risk factor measured by a chromogenic and a coagulant assay
|
| Slaoui M., Le Querrec A., Gautier P., Borel-Derlon A. |
| |
|
Comparison of hemorrhagic symptoms in obligatory carriers of type 1 and type 3 von willebrand disease (VWD): results from a collaborative, international, multicenter study
|
| Tosetto A., Castaman G., Cappelletti A., Battle J., Baudo F., Blomback M., Castillo R., De Bosch N., Federici A. B., Eikenboom J. C. J., Lethagen S., Lusher J., Linari S., Monteagudo J., Nishino M., Srivastava A., Rodeghiero F. |
| |
|
Comparison of inherited and acquired thrombophilia in cerebral venous thrombosis and pulmonary embolism or deep vein thrombosis of the leg
|
| Martin-Toutain I., Favier R., Jacob N., Vu T., Couty M. C., Ankri A. |
| |
|
Comparison of magnetic resonance characteristics of the vessel wall between patients with classic and dilatative atherosclerosis
|
| Kozak M., Stalc J., Tominc U., Blinc A. |
| |
|
Comparison of normal values for coagulation measurements in a variety of evacuated containers
|
| Munro R., Hardingham S., Dorward N. R., Morris K. |
| |
|
Comparison of platelet aggregation in venous and arterial blood
|
| Kobzar G., Mardla V., Rätsep I., Samel N. |
| |
|
Comparison of template bleeding time and PFA-100 as screening tests in 175 consecutive patients with hereditary mucocutaneous hemorrhages (MCH)
|
| Mezzano D., Quiroga T., Muñoz B., Rodríguez S., Panes O., Martínez C., Goycoolea M., Martínez M., Pereira J. |
| |
|
Comparison of TFPI release of various LMW heparins based on the molecular weight distribution of the LMW heparins and a model describing the TFPI release according to molecular mass
|
| Larnkjaer A., Johansen K. B., Mousa S. A. |
| |
|
Comparison of the binding character of triflavin on resting and activated aIIbb3 integrin in human platelets by electron microscopy
|
| Fong T. H., Hsiao G., Sheu J. R. |
| |
|
Comparison of the clinical utility of two D-dimer tests (IL Test and Simpify) in the diagnosis of pulmonary embolism
|
| Hogg K., Dawson D., Mackway-Jones K. |
| |
|
Comparison of the point-of-care method for oral anti-coagulation control with the conventional method
|
| Rached R. A., De Piano L. P. A., Cavalheiro-Fílho C., Rached R. D. V. A., Strunz C. M. C., Grinberg M., Chamone D. A. F. |
| |
|
Comparison of two methods to assess platelet activation during and after CABG
|
| Gruenewald M., Goedje O., Gallmeier G. U., Ruf A., Reitenauer M., Gruenewald A., Konegen A., Griesshammer M. |
| |
|
Comparison of von Willebrand factor activities measured by ristocetin cofactor assay and two different VWF-collagen-binding-assays in VWF/FVIII-concentrates
|
| Suiter T., Budde U., Metzner H. J., Muysers C., Walter O. |
| |
|
Competitive activation of IX and X by the extrinsic pathway. Studies of the differential regulation of enzyme and products by antithrombin III and tissue factor pathway inhibitor reveal that active IXa is a major reaction product of this pathway
|
| Lu G., Broze G. J., Krishnaswamy S. |
| |
|
Complement C3 and its relationship to features of the insulin resistance syndrome and cardiovascular disease
|
| Carter A. M., Futers T. S., Ajjan R., Brown J. M., Grant P. J. |
| |
|
Complex formation of Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) with fibrin(ogen)
|
| Mosnier L. O., Cox L., Marx P. F., Meijers J. C. M., Bouma B. N., Von Dem Borne P. A. KR. |
| |
|
Complex of Glycoprotein IIb/IIIa – von Willebrand factor (GP IIb/IIIa-vWF) in blood of patients with ischemic heart disease
|
| Bokarev I., Kiselyova Z., Nesova T. |
| |
|
Complexity of the genetic contribution to Factor VII deficiency in two Spanish families: clinical and biological implications
|
| Sabater-Lleal M., Martinez-Marchan E., Martinez-Sanchez E., Coll I., Vallve C., Mateo J., Souto J. C., Fontcuberta J., Soria J. M. |
| |
|
Complications of plasma exchange in thrombotic thrombocytopenic purpura–hemolytic uremic syndrome (TTP-HUS): A study of 149 consecutive patients 1996–2002
|
| Vesely S., George J. N., Duvall D. |
| |
|
Compound 48/80 inhibits thrombosis in balloon-injured arteries of hypercholesterolemic rabbits by inhibiting TF/FVIIa-mediated coagulation
|
| Gibson G., Potoczak R., Peng Y. W., Janiczek N., Juneau P., Leadley R., Chi L. |
| |
|
Compound heterozygous Protein C deficiency resulting in neonatal purpura fulminans: identification of a novel mutation and its functional consequences
|
| Surdhar G., Kinning E., Enayat M. S., Hill F. G. H., Williams M. D. |
| |
|
Compression bandaging in the acute phase of deep-vein thrombosis reduces symptoms but does not decrease venous outflow resistance and thrombosisscore as a proxy of the post-trombotic syndrome
|
| Roumen-Klappe E., Den Heijer M., Holewijn S., Wollersheim H. |
| |
|
Compression ultrasound in diagnosis of asymptomatic deep venous thrombosis
|
| Tomkowski W. Z., Lensing A. W. A., Wisniewska J., Kober J., Makek G., Oniszh K., Burakowska B., Kus J., Zielinski J., Roszkowski K., Kuca P. |
| |
|
Concluding comments
|
| Breddin H.K., Samama M.M. |
| |
|
Concomitant activation of both the P2Y1-driven Gq and the P2Y12-driven Gi pathways is necessary for normal ADP-induced mobilization of platelet cytoplasmic Ca2+
|
| Cattaneo M., Lombardi R., Lecchi A. |
| |
|
Concomitant use of mechanical and pharmacological methods of prophylaxis for venous thromboembolism after total hip and knee arthroplasty: Findings from the Global Orthopaedic Registry (GLORY)
|
| Cushner F., Friedman R., Anderson F., Prybyla D., White K. |
| |
|
Conditioning of endothelial cells by different levels of fluid shear stress modulates their ability to induce each stage of neutrophil adhesion and migration in response to TNF-a but not IL1-b
|
| Sheikh S., Gale Z., Rainger G. E., Nash G. B. |
| |
|
Cone and plate(let) analyzer as a diagnostic tool in various types of thrombotic thrombocytopenic purpura and haemolytic uremic syndrome
|
| Shenkman B., Budde U., Angerhaus D., Lubetsky A., Savion N., Seligsohn U., Varon D. |
| |
|
Conformational basis of homozygous heparin cofactor II deficiency confirms critical role of P17 glutamate in serpins
|
| Corral J., González-Conejero R., Aznar J., Carrell R. W., Huntington J. A., Vicente V. |
| |
|
Congenital afibrinogenemia, identification of four novel homozygous mutations in the fibrinogen gene cluster: three point mutations and a 15-kb deletion
|
| Duga S., Asselta R., Spena S., Peyvandi F., Malcovati M., Mannucci P. M., Tenchini M. L. |
| |
|
Congenital afibrinogenemia: expression and analysis of novel mutations affecting fibrinogen assembly or secretion
|
| Vu D., de Moerloose P., Abu-Libdeh B., Bouchardy I., Taher A., Bolton-Maggs P. H. B., Morris M. A., Neerman-Arbez M. |
| |
|
Congenital defect of inferior vena cava and thrombophilia Leiden
|
| Makris P. E., Girtovitis F., Lazaraki G., Kosmidou M., Anestakis D., Papadopoulos A., Ziakas G. |
| |
|
Congenital factor VII deficiency and thrombosis. Description of a novel mutation
|
| Escobar M., Ulmasov B., Kuppuswamy M. N., Bajaj M. S., Fisher L., Bajaj S. P. |
| |
|
Conjoint analysis: a new technique to quantify individual's preferences, to develop outcome measures and to determine optimal treatment patterns in hemophilia
|
| Gringeri A., Scalone L., Mantovani L. G. |
| |
|
Connective tissue growth factor (CTGF) expression in synovial lining is down regulated by residues D793-P824 derived from thrombospondin-1 type-3 repeats (TSP1) in an experimental animal model of rheumatoid arthritis
|
| Manns J. M., Barbe M. F., Safadi F. F., Uknis A. B., Popoff S. N., Dela Cadena R. A. |
| |
|
Consequences of expression of hepsin in murine vascular systems
|
| Su K., Yu I. S., Lin S. R., Huang H. Y., Huang P. H., Hong G., Lin S. W. |
| |
|
Considerations in the standardization of the functional and immunologic assays for human procarboxypeptidase U. Diagnostic implications
|
| Tobu M., Florian-Kujawski M. R., Hoppensteadt D. A., Ma Q., Iqbal O., Bacher P., Fareed J. |
| |
|
Consistency of efficacy of extended thromboprophylaxis with fondaparinux (Arixtra) in prevention of venous thromboembolism (VTE) after hip fracture surgery according to different composite efficacy endpoints: the PENTHIFRA-PLUS study
|
| Eriksson B. I., Lassen M. R. |
| |
|
Construction and characterization of a new recombinant plasminogen activator composed of an antifibrin single-chain antibody and a low molecular weight form single-chain urokinase
|
| Hagemeyer C. E., Tomic I., Weirich U., Graeber J., Bode C., Peter K. |
| |
|
Contact system activation, FXIIa and plasma kallikrein produce enhanced fibrinolysis in urokinase induced fibrinolysis in thromboelastography: (UKIFTEG)
|
| Gallimore M., Jones D. W., Tappenden K., Winter M. |
| |
|
Contact-dependant signalling during late events of platelet activation
|
| Prevost N., Woulfe D., Tognolini M., Brass L. F. |
| |
|
Contemporary total hip and knee replacement in A patients with haemophilia and high titre of inhibitors to FVIII by using recombinant FVIIa (novoseven) continuous infusion
|
| Tagariello G., Bisson R., Radossi P., Petris U., Zanardo G., De Biasi E., Risato R., Davoli P. G. |
| |
|
Continuing clinical evaluation of an advanced category recombinant FVIII, antihemophilic factor (recombinant) plasma/albumin-free method (rAHF-PFM) in previously treated patients (PTPs)
|
| Shapiro A., Collins P., Tarantino M., Gruppo R., Hay C., Berntorp E., Retzios A., Sensel M., Tonetta S., Ewenstein B. |
| |
|
Continuous infusion of B-domain deleted recombinant factor VIII (ReFacto®) for surgical procedures in pediatric patients with severe hemophilia A
|
| De Alarcon P., Sennett M. |
| |
|
Contrast media and compounds containing iodine prevent fibrin formation
|
| Stemberger A., Stemberger M., Stemberger M., Brandt S., Thalhammer A. |
| |
|
Contribution of factor V deficiency to the thrombotic risk associated with factor V HR2
|
| Faioni E. M., Castaman G., Asti D., Lussana F., Rodeghiero F. |
| |
|
Contribution of genetic factors to mild hyperhomocysteinemia
|
| Gellekink H., Kluijtmans L. A. J., Blom H. J., Den Heijer M. |
| |
|
Control of Factor Xa activity by heparin in plasma is related to the inhibition of free Factor Xa
|
| Fiore M. M., Kakkar V. V. |
| |
|
Control of von Willebrand factor multimer size by a fibronectin related substance
|
| Kempfer A., Farías C. E., Carballo G. A., Amaral M. M., Lazzari M. A. |
| |
|
Convulxin binds to native, human glycoprotein Iba (GPIba)
|
| Kunicki T. J., Kanaji S., Kanaji T., Furihata K., Ware J. L. |
| |
|
Copper binding site(s) in factor VIII involved in the regulation of cofactor specific activity
|
| Wakabayashi H., Zhou Q., Fay P. J. |
| |
|
Co-prescription of drugs with potential interaction with oral anti-coagulants in a health maintenance system from Córdoba, Argentina
|
| Casanegra A., Tabares A. |
| |
|
Coronary risk prediction and the role of C-reactive protein
|
| Van Der Bom J. G., Van Der Schouw Y. T., Moons K. G. M., Roest M., Van Der A. D., Voorbij H. A. M. |
| |
|
Coronary t-PA release is triggered by cardiac sympathetic nerve stimulation
|
| Bjorkman J. A., Jern S., Jern C. |
| |
|
Correction of coagulation, as measured by the thromboelastogram, with low dose recombinant VIIa treatment in a patient with a factor VIII inhibitor
|
| Young L., Devenie G., Pitcher L., Ockelford P., Harper P. |
| |
|
Correlation between anti-coagulant therapeutic range and Prothrombin Fragment 1 + 2 in Japanese patients with Cardioembolic Stroke
|
| Nagao T., Katayama Y., Yokochi M. |
| |
|
Correlation between endothelial haemostatic markers in patients with coronary heart disease
|
| Korzh O., Bondarenko T., Korzh I. |
| |
|
Correlation between internal carotid artery stenosis and hematological risk factors for thrombosis (CAST study): final results
|
| Camporese G., Tormene D., Verlato F., Zerbinati P., Salmistraro G., Luni S., Simioni P., Girolami A., Andreozzi G. M. |
| |
|
Correlation between SVCAM, SICAM plasma levels, the outcome of treadmill test and the systolic function of left ventricular (LV) in patients with coronary artery disease
|
| Tsoutsoumanou K., Sfiridaki K., Dermitzakis A., Zaharaki A., Avramakis G., Meidanis K., Papakostanti E., Kantidaki E., Livadiotaki A., Nikolaidis G. |
| |
|
Correlation of parameters characterizing healthy newborns with cord blood concentration of thrombin activatable fibrinolysis inhibitor (TAFI)
|
| Knoefler R., Ludwig K., Kostka H., Siegert G., Kuhlisch E., Suttorp M. |
| |
|
Correlation of supra-therapeutic (ST) International Normalized Ratio (INR) with vitamin-K-dependent factors (VKDF)
|
| Sarode R., Rawal A., Lee R., Uchal L., Frenkel E. P. |
| |
|
Correlation of the serum ferritin (SF) levels with cholesterol and body mass index (BMI) in patients with advanced atherosclerosis
|
| Zacharski L. R., Chow B., Shamayeva G., Howes P., Balestra D. |
| |
|
Correlation SVCAM, SICAM plasma levels with the outcome of treadmill test and with attitudinal factors for coronary artery disease in patients without previous history of ischemic heart disease
|
| Tsoutsoumanou K., Sfiridaki K., Avramakis G., Zaharaki A., Dermitzakis A., Livadiotaki A., Kandidaki E., Lambrogiannakis E., Ploumidis L., Nikolaidis G. |
| |
|
Co-segregation of Von Willebrands disease type 1 phenotype and Von Willebrand factor gene haplotypes: first results from the multicenter study molecular and clinical markers for the diagnosis and management of type 1 Von Willebrands disease
|
| Eikenboom J. C. J., Gomez Garcia E. B., Van Marion V., Peake I. R., Goodeve A., Rodeghiero F., Castaman G., Federici A. B., Batlle J., Meyer D., Mazurier C., Goudemand J., Schneppenheim R., Budde U., Ingerslev J., Vorlova Z., Habart D., Holmberg L., Lethagen S., Pasi J., Hill F. |
| |
|
Cost analysis of the treatment of patients with post–thrombotic syndrome in Brazil
|
| Ramacciotti E., Toledo E., Caiafa J., Moura L., Araújo G., Dietrich-Neto F. |
| |
|
Cost-effectiveness in establishing carrier detection and prenatal diagnosis services in a developing country with limited health resources
|
| Sasankul W., Chuansumrit A., Ajjimakorn S., Krasaesub S., Sirachainan N., Chotsupakarn S., Kadegasem P., Rurgkhum S. |
| |
|
Cost-effectiveness of fondaparinux (Arixtra®) compared with enoxaparin as prophylaxis against venous thromboembolism following major orthopedic surgery
|
| Annemans L., De Groot K. |
| |
|
Cost-effectiveness of venous thromboembolism prophylaxis after total hip replacement
|
| Caprini J. A., Arcelus J. I., Kudrna J. C., Sehgal L. R., Oyslender M., Maksimovic D., Macdougall A. |
| |
|
C-Reactive protein (CRP) is not a strong inducer of tissue factor in human monocytes
|
| Paffen E., Vos H. L., Bertina R. M. |
| |
|
C-reactive protein (CRP) may predict death from cancer in men with lower extremity arterial disease
|
| Maccallum P. K., Cooper J. A., Price C., Meade T. W. |
| |
|
C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the Cardiovascular Health Study (CHS)
|
| Cushman M., Arnold A. M., Manolio T. A., Psaty B. M., Kuller L. H., Polak J. F., Burke G. L., Tracy R. P. |
| |
|
C-reactive protein in patients with venous thromboembolism
|
| Vormittag R., Vukovich T., Eichinger S., Lehr S., Pabinger I., Minar E. |
| |
|
C-reactive protein induces the expression of tissue factor and interleukin-8 in the lung
|
| Gabazza E. C., Nakano M., Ohta K., Hayashi T., Kamada H., Taguchi O., Adachi Y., Suzuki K. |
| |
|
C-reactive protein: a link between inflammation and thrombosis formation in patients with unstable angina?
|
| El Ali M., Teodoridis T., Karabinos I., Koulouris S., Krandis A., Lekatsas J., Exadaktylos N., Cokkinou V. |
| |
|
Critical lower limb ischemia caused by essential thrombocytosis and successful limb salvage using angiographic-guided intra-arterial thrombolysis with rTPA
|
| Wong L., Sathar J., Beh S. J., Chang K. M., Purusuthoman V. |
| |
|
Cross–species interactions of FXIII and fibrinogen
|
| Lewis K. B., Gasper S. R., Meengs B. L., Stamm M., Bishop P. D. |
| |
|
Cross-linking of fibrin by factor XIII and its effect on fibrin structure/function
|
| Lim B. C. B., Ariens R. A. S., Connell S. D., Smith D. A. M., Weisel J. W., Grant P. J. |
| |
|
Cross-linking of GPIb by echicetin/biotinylated-IgMk/avidin induces strong GPIIb/IIIa activation and platelet aggregation
|
| Navdaev A., Clemetson K. J. |
| |
|
Cross-reactivity of anti-lepirudin antibodies from patients with heparin-induced thrombocytopenia with bivalirudin
|
| Eichler P., Lubenow N., Strobel U., Greinacher A. |
| |
|
Cross-talk between alpha2beta1 integrin and GPVI receptors regulates actin polymerization through Rho GTPase and MAP kinase Erk1/2 signaling pathways in human megakaryocytes
|
| Sabri S., Pencreach E., Jandrot-Perrus M., Bertoglio J., Farndale R. W., Helvig B., Debili N., Vainchenker W. |
| |
|
Crucial role of the ADP receptor P2Y1 in platelet adhesion and signaling under high flow
|
| Mazzucato M., Cozzi M. R., Pradella P., Ruggeri Z. M., De Marco L. |
| |
|
Crystal structure at 1.7 A of aggretin, a heterodimeric C-type lectin snake venom protein
|
| Papagrigoriou E., Nadvaev A., Clemetson K. J., Emsley J. |
| |
|
Crystal structure of a disintegrin from snake venom containing a cell adhesion recognition sequence RGD
|
| Mizuno H., Fujii Y., Okuda D., Fujimoto Z., Horii K., Morita T. |
| |
|
Crystal structure of benzamidine-Factor VIIa/soluble tissue factor at 1.87 Å resolution: mapping of calcium, magnesium, sodium, and zinc sites in the Factor VIIa structure
|
| Bajaj S. P., Padmanabhan K., Bajaj M. S., Liesum A., Dumas J., Prevost D., Schreuder H. |
| |
|
Crystal structure of the amino terminal domain of glycoprotein Iba in complex with a-thrombin
|
| Celikel R., Mcclintock R. A., Roberts J. R., Ware J., Varughese K. I., Ruggeri A. M. |
| |
|
CTRP1 – a vascular wall protein that can prevent platelet thrombosis without causing bleeding
|
| Meehan W. P., Knitter G., Lasser G. W., Lewis K. B., Bishop P. D., Marzec U. M., Hanson S. R., Fruebis J. |
| |
|
Current challenges in the management of thromboembolic disease
|
| Ansell J. |
| |
|
Current concentrates: how much better can they get?
|
| White II G. C. |
| |
|
Current Concepts of the Pathophysiology and Management of Sepsis
|
| TBA |
| |
|
Current processes and the future of manufacturing for recombinant clotting factors
|
| Negrier C |
| |
|
CYP2C9 polymorphisms have differential effects on acenocoumarol metabolism, but do not increase bleeding risk
|
| Van Der Heijden J. F., Hutten B. A., Schmits S., Remkes M. G. H., Reitsma P. H. |
| |
|
CYP2C9 polymorphisms have differential effects on the quality of acenocoumarol treatment
|
| Van Der Heijden J., Hutten B. A., Schmits S., Remkes M. G. H., Reitsma P. H. |
| |
|
Cys61stop is the first identified nonsense mutation in the factor X gene causing severe factor X deficiency in 3 unrelated homozygotes of Arab origin
|
| Zivelin A., Salomon O., Kenet G., Gillis S., Varon D., Goldschmidt N., Kovalsky V., Lijima K., Seligsohn U. |
| |
|
Cysteine–homocysteine ratio in patients with C677T mutation of the MTHFR gene
|
| Alberto M. F., Casais P., Salviú M. J., Meschengieser S. S., Blanco A. N., Aixalá M., Lazzari M. A. |
| |
|
Cytokine gene expression and production in human LPS-stimulated mononuclear cells are inhibited by sulfated heparin-like semi-synthetic derivatives
|
| Gori A., Attanasio M., Gazzini A., Giusti B., Lucarini L., Miletti S., Chini J., Manoni M., Abbate R., Gensini G. F. |
| |
|
Cytoskeletal regulation of the adhesive interactions between the platelet GPIb/V/IX receptor and von Willebrand factor
|
| Cranmer S. L., Mistry N., Pikovski I., Santer M., Lanza F., Salem H. H., Jackson S. P. |
| |
